Organization
Evive Biotechnology
4 clinical trials
Clinical trial
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast CancerStatus: Completed, Estimated PCD: 2013-12-01
Clinical trial
A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyStatus: Completed, Estimated PCD: 2019-09-25
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of F-652 in Subjects With COVID-19 PneumoniaStatus: Withdrawn, Estimated PCD: 2022-04-08
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19Status: Terminated, Estimated PCD: 2021-03-24